Syros Pharmaceuticals, Inc. (0S90.F)
| Previous Close | 3.6400 |
| Open | 3.7100 |
| Bid | 3.7100 x N/A |
| Ask | 3.8700 x N/A |
| Day's Range | 3.7100 - 3.7100 |
| 52 Week Range | 2.3000 - 6.7300 |
| Volume | |
| Avg. Volume | 1 |
| Market Cap | 77.066M |
| Beta (5Y Monthly) | 1.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings Date | Nov 13, 2023 - Nov 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., September 07, 2023--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 20,650 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq List
- Thomson Reuters StreetEvents
Q2 2023 Syros Pharmaceuticals Inc Earnings Call
Q2 2023 Syros Pharmaceuticals Inc Earnings Call
ZacksSyros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -17.12% and 10.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
